Lynch syndrome is the most common cause of inherited colorectal cancer (CRC) and is due to germline mutations in mismatch repair (MMR) genes. Early Lynch syndrome diagnosis and appropriate CRC surveillance improves mortality. Traditional qualitative clinical criteria including Amsterdam and Bethesda guidelines may miss mutation carriers. Recently, quantitative predictive models including MMRPredict, PREMM(1,2,6), and MMRPro were developed to facilitate diagnosis. However, these models remain to be externally validated in the United States. Therefore, we evaluated the test characteristics of Lynch syndrome predictive models in a tertiary referral group at two US academic centers.
INTRODUCTION
Lynch syndrome (also called hereditary nonpolyposis colorectal cancer (CRC) or HNPCC) is the most common cause of familial CRC, accounting for 3 -5 % of all CRC cases ( 1 ) . It is an autosomal dominant syndrome that imparts a 60 -80 % lifetime risk of CRC, 60 -70 % risk of endometrial cancer, and ~ 15 % risk for other extracolonic neoplasms including ovarian, small bowel, gastric, biliary, central nervous system, sebaceous gland, renal, and renal collecting system ( 2,3 ). Lynch syndrome is caused by germline mutations in DNA mismatch repair (MMR) genes including h MLH1 and h MSH2 (80 % of cases), h MSH6 (5 -10 % of cases) and rarely h PMS2 . In ~ 10 -15 % of patients meeting clinical criteria for Lynch syndrome, no mutations in MMR genes are identifi ed ( 4 ) . Loss of MMR function results in errors in genomic replication known as microsatellite instability (MSI-H), which can be detected in 90 % of Lynch-associated CRC. While suggestive, this fi nding is not Performance of Lynch Syndrome Predictive Models in a Multi-Center US Referral Population diagnostic, as up to 10 -20 % of sporadic CRCs also display MSI-H features due to epigenetic silencing by promoter hypermethylation ( 5 ) .
Given the diversity in family and personal histories of cancer, lack of exclusive pathologic features, and known mortality benefi t of an early diagnosis of Lynch syndrome ( 6 ), two qualitative clinical criteria, the Amsterdam and Bethesda guidelines, were developed to help facilitate diagnosis. However, there have been concerns about sensitivity, specifi city, and predictive values of these original guidelines ( 6 ) . Mutation carriers who do not fulfi ll these criteria, 22 % in one large cohort ( 7 ) , remain at signifi cantly increased risk for CRC ( 8 ) . Factors such as small families, adoption, unknown family history, newly arisen or undiscovered mutations, and patients without available tumor data limit the value of these clinical and pathologic methods ( 9 ) .
With increasing knowledge and understanding of the biologic basis of Lynch syndrome, three new quantitative predictive models, MMRPredict(9), PREMM(1,2,6)(15), and MMRPro (16) have emerged to help identify potential mutation carriers. Similar to predictive models in hereditary breast -ovarian syndrome such as BRCApro, the goal is a simple, accurate, clinically useful tool for predicting the likelihood of Lynch syndrome. Given that CRC mortality can be cost eff ectively averted in Lynch syndrome patients by early and intensive surveillance ( 6, 10 ) , these three models represent potential advancement in screening and diagnosis. Overall, previous validation studies outside of the United States in both modest-sized referral populations ( 11, 12 ) as well as larger, population-based studies ( 13, 14 ) have found similar test characteristics for all three models. However, they have not been systematically validated in larger, US-based referral populations, nor have they examined the updated PREMM(1,2,6) algorithm, which now includes h MSH6 ( 15 ) . Our aim was to evaluate the testing characteristics of these models in a multi-center, tertiary referral study group in the United States screened through the University of California at San Francisco and the University of Chicago ' s Cancer Risk Clinics.
METHODS
We obtained the pedigrees of 230 consecutive patients who underwent germline mutation testing at the University of California at San Francisco ' s Colorectal Cancer Prevention Program and the University of Chicago ' s Cancer Risk Clinic. All patients were referred based on a clinical history or tumor information suggestive of a possible diagnosis of Lynch syndrome. Individuals were evaluated by a genetic counselor who obtained detailed family histories and, using Progeny (Progeny Soft ware, South Bend, IN), recorded pedigree information on the proband and both aff ected and unaff ected relatives. Germline mutation analysis was performed by Myriad Labs (Salt Lake City, UT) or the Mayo Clinic Molecular Genetics Laboratory (Rochester, MN). Mutation risk scores were calculated for each of the three predictive models. MMRPredict and PREMM (1, 2, 6) When data were missing or unknown, a best faith assumption was made. Th ese assumptions were based on routine practice in a genetics clinic, as the model builders do not give guidance on inputting missing data. In the case of MMRPro, when age was unknown, it was estimated based on a 30-year separation between generations. With MMRPredict, when tumor location was unknown, scores were calculated using both proximal and distal locations, then the average between the two was used. When MMR mutation analysis revealed a variant result, these were considered as positive fi ndings (two probands).
Receiver-operator characteristic curves and area under receiveroperator characteristic curves (AUCs) were generated for the three models. We calculated specifi city, positive likelihood ratios, and resultant model scores across a range of sensitivities (90, 95, and 98 % ). We compared characteristics of individuals missed by all three models with those who were captured by the models. Moreover, we compared characteristics of individuals missed exclusively by each of the predictive models. P values were calculated using two-tailed Fisher ' s exact or χ 2 tests and unpaired t -tests for categorical and continuous data, respectively. All statistical analysis was performed using STATA 10.1 (College Station, TX).
RESULTS
Clinical characteristics of patients included in this study are shown in Table 1 . Of the 230 patients evaluated, 113 were found to have germline mutations associated with Lynch syndrome with an overall prevalence of 49 % . Our population included 80 males and 150 females of which 50 and 49 % , respectively, were found to be mutation positive. While the majority of patients were Caucasian, 18 % were Asian (10 probands), Hispanic (16 probands), or African Americans (15 probands). Th e MMR mutation spectrum included 42 % h MLH1 , 45 % h MSH2 , and 13 % h MSH6.
Probands harboring MMR mutations diff ered from those who did not in several important ways. Probands with mutations trended toward higher rates of CRC (69 vs. 57 % , P = 0.07) and their CRC occurred at a younger age (43 vs. 50, P = 0.0001). Mutation carriers also had higher rates of endometrial cancer (23 vs. 12 % , P = 0.03) and trended toward a younger age of disease onset (45 vs.
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51, P = 0.16). Rates of other Lynch-associated tumors were similar in both the groups (15 vs. 10 % , P = 0.32). Family histories were also signifi cantly diff erent between mutation carriers and noncarriers. Families with mutations had higher rates of fi rst-degree relatives with CRC (32 vs. 17 % , P = 0.0001) at younger mean ages (47 vs. 53, P = 0.001). Rates of endometrial cancer in fi rst-degree relatives were also higher in those with mutations (13 vs. 4 % , P = 0.0002). Higher rates of CRC (18 vs. 8 % , P = 0.0001) and younger age of onset (46 vs. 61, P = 0.0001) were also noted in second-degree relatives of mutation carriers.
Receiver-operator characteristic analysis for all models is shown in MMRPredict, PREMM(1,2,6), and MMRPro provide a quantitative estimate of MMR mutation risk thus, for a given population, physicians and patients can determine a predicted risk threshold above which consideration for germline genetic testing would be appropriate. We calculated testing characteristics for each model across a range of sensitivities in our referral population. Shown in Table 2 are specifi city, positive likelihood ratio, and predicted risk score ( % ) when sensitivity is set at 90, 95, and 98 % . For MMRPredict to obtain a sensitivity of 90 % , a threshold for mutation testing of > 4 % would provide a specifi city of 29 % and a positive likelihood ratio of 1.3. At the highest sensitivity (98 % ), the specifi city drops to 10 % with a risk score cutoff of > 1 % . For PREMM(1,2,6), a cutoff of > 6 % would be 90 % sensitive and 38 % specifi c with a positive likelihood ratio of 1.4. At sensitivities of 95 and 98 % , the specifi city is 0 % with a cutoff risk score of > 0 % . For MMRPro, a cutoff score of > 7 % would be 90 % sensitive and 36 % specifi c. For a 98 % sensitive test using MMRPro, as with PREMM(1,2,6), all patients would require genetic testing as the risk score cutoff is > 0 % .
Th e authors of MMRPredict and PREMM(1,2,6) also provide guidance for appropriate cutoff s leading to further evaluation. MMRPredict describes > 5 % to be the " optimal combination of clinical utility and effi ciency " ( 9 ) . In our cohort, using > 5 % as a diagnostic threshold for MMRPredict resulted in a sensitivity of 85 % , specifi city of 35 % , and positive likelihood ratio of 1.3. Th e authors of PREMM(1,2,6) suggest a cutoff of > 5 % " may be a reasonable threshold " for further genetic testing and, in our cohort, this resulted in a sensitivity of 90 % , specifi city of 37 % , and positive likelihood ratio of 1.4 ( 15 ) . Th e authors of MMRPro report " thresholds should be chosen based on individual circumstances, " 
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but do mention their model performed with higher sensitivity and specifi city than Bethesda, with MSI in the range of > 35 % to > 62 % cutoff ( 16 ) . In our cohort, these thresholds would result in a sensitivity of 65 -78 % , specifi city of 68 -84 % , and positive likelihood ratio of 2.4 -4.2 for MMRPro.
Testing characteristics were calculated for the qualitative Amsterdam and Bethesda guidelines. Amsterdam criteria were fulfi lled in 148 of 230 probands mandating less genetic testing (147 of 230, 64 % ) with an improved specifi city (52 % ). Th ese gains, however, were at the expense of sensitivity, which proved to be only 81 % . Bethesda guidelines presented a diff erent set of limitations requiring almost universal germline testing (216 of 230, 94 % ), with subsequent high sensitivity (99 % ) but low specifi city (10 % ). In comparison, the quantitative predictive models would require testing between 76 -85 % of the probands in our highly selected population to obtain a sensitivity of > 90 % .
In order to determine the characteristics of individuals missed by the models, we compared missed mutation carriers with those identifi ed by the models at cutoff scores corresponding to > 90 % sensitivity. Twenty-two mutation carriers were missed by at least one model, seven by at least two models, and two by all three models. Of the seven mutation carriers missed by at least two models, two had hMLH1 mutations, four had h MSH2 mutations, and one had an h MSH6 mutation. Mutation carriers missed by at least two models compared with subjects identifi ed by the models had increased rates of CRC (6 / 7 (86 % ) vs. 78 / 113 (69 % ), respectively) at older ages of onset (52 years vs. 43 years, respectively). Th ere were no cases of endometrial cancer or other Lynch syndrome-associated malignancy in missed mutation carriers. Th eir family histories revealed fewer fi rst-and second-degree relatives with CRC (14 vs. 32 % and 15 vs. 18 % , respectively) at older ages of onset (55 vs. 47 and 80 vs. 46, respectively). Th ere was no family history of endometrial cancer and fi rst-and second-degree relatives had similar rates of other Lynch syndrome-associated tumors.
In order to determine if diff erent models fi t a pattern of who they missed, we considered characteristics of subjects missed exclusively by each model ( Table 3 ). Four mutation carriers were missed exclusively by MMRPredict at a cutoff score of > 4 % . Two of these missed subjects had a personal history of endometrial cancer, which is not included in the MMRPredict model. PREMM (1,2,6 ), when output threshold was > 6 % , missed fi ve patients that were detected by MMRPro and MMRPredict. PREMM(1,2,6) did not miss any patients with personal history of endometrial cancer nor h MSH6 mutation carriers. Only one of the fi ve subjects missed by PREMM (1,2,6 ) had other Lynch-associated tumors. MMRPro missed six mutation carriers at a cutoff score of > 7 % predicted risk. Th ese patients have increased rates of other Lynch-associated tumors and their family histories revealed fewer individuals aff ected by CRC. Like PREMM(1,2,6), MMRPro did not miss any h MSH6 mutation carriers.
We also considered test characteristics in African Americans given limited information about racial diff erences in Lynch syndrome. A total of 15 African American probands were tested of which nine (60 % ) were found to be mutation positive. MMRPredict, PREMM(1,2,6), and MMRPro were all 100 % sensitive with AUCs of 0.89, 0.89, and 0.93, respectively, in our African American patients.
DISCUSSION
In a large group of consecutive patients who presented for hereditary cancer evaluation and subsequent germline mutation testing at the University of California at San Francisco and University of Chicago ' s Cancer Risk Clinics, our data suggest that MMRPredict, PREMM (1, 2, 6) , and MMRPro performed similarly in predicting MMR mutation carriers with AUCs between 0.76 and 0.82. One benefi t of these newer quantitative models over previous clinical criteria is the clinician ' s ability to determine a threshold for further genetic evaluation that is appropriate in a given population. In our referral cohort, a sensitivity of > 90 % resulted in a similar specificity and positive likelihood ratio in all three predictive models. When compared with qualitative Bethesda and Amsterdam criteria, we observed improved testing characteristics. Bethesda, while 99 % sensitive, required almost universal testing and had limited specifi city. While Amsterdam tested signifi cantly fewer patients, its sensitivity was only 81 % , which is too low for screening purposes. Th ese results are similar to those reported in two smaller-scale referral populations from Canada ( 11, 12 ) and, while representing a highly selected referral population, remain relevant to gastroenterologists and other health-care providers who must risk-stratify patients for Lynch syndrome in clinical practice.
Seven mutation carriers were missed by two or more models and represent an important cohort of patients that may be diffi cult to screen using clinical criteria. While these carriers had higher rates of CRC, they occur at an older age of onset, which is less suspicious from the models ' standpoint. Additionally, they exhibited no personal history of endometrial cancer or other Lynch-associated Khan et al.
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our population, it functioned particularly well in h MSH6 , missing no carriers uniquely. It is also the only model that accounts for Lynch-associated cancers beyond EC and CRC, which is illustrated by its improved performance in patients aff ected by these tumors. PREMM(1,2,6) ' s strengths are its simple, web-based platform, and ability to account for other Lynch-associated tumors. PREMM(1,2,6) may be less informative in patients with MSI or immunohistochemistry testing as, in contrast to MMRPredict and MMRPro, it does not incorporate this tumor data. For genetic counselors, MMRPro ' s benefi ts include its ability to quantify risk for patients even when tumor or germline testing is negative. Th e algorithm also takes into account age and cancer status of all fi rst-and second-degree relatives individually, as is illustrated by the reduced rates of CRC-aff ected family members in its missed carriers. However, it is signifi cantly more time consuming, requiring a complete family pedigree to provide thorough risk estimates. Additionally, MMRPro is unable to incorporate other Lynch-associated malignancies, explaining their increased tumors. Th eir family histories were also less suggestive with lower rates of CRC and older ages of onset, no cases of endometrial cancer, and similar rates of other Lynch-associated tumors. Mutation and gender distribution appeared similar to our overall population, although these fi ndings are limited by the small sample size. While fi ve of the seven met Bethesda criteria, only one met Amsterdam.
Although the overall performance was similar among the three models, important diff erences should be noted as they aff ect application of these models in clinical practice. Th ese features are summarized in Table 4 . MMRPredict only accounts for probands with CRC when calculating risk scores and, subsequently, misses carriers with a personal history of endometrial cancer or any history of other Lynch-associated tumors. MMRPredict ' s strengths are its fast, simple, web-based platform and ability to incorporate tumor information such as location and MSI / immunohistochemistry testing when available. It is less suited for probands with strong, but remote, family histories or in those with numerous Lynchassociated tumors beyond CRC.
PREMM (1, 2, 6) , like MMRPredict, is available as a web-based module and can rapidly assess mutation risk for h MLH1 , h MSH2 , and, more recently, has been updated to include h MSH6 ( 15 ). In 
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COLON/SMALL BOWEL prevalence in mutation carriers missed by MMRPro. MMRPro is most valuable as an attempt to quantify risk in tumor or germlinenegative probands or when extensive pedigree information is available. It is less suited for families with signifi cant Lynch-associated tumors beyond endometrial cancer or CRC and when time for assessment is limited. Th ere are strengths and limitations to our study. We included consecutive individuals from two large, geographically distinct centers in the United States. Subjects ' personal and family histories were well characterized and included several racial and ethnic backgrounds. Moreover, we included the most recent PREMM (1,2,6 ) model, which has not previously been validated. One limitation is the highly select referral population, which, while relevant to many centers evaluating suspected Lynch syndrome, may not apply to a more generalized patient population. Moreover, we had only a small number of subjects that were missed by the models. In addition, while all patients underwent testing for h MLH1 , h MSH2 , and h MSH6 , these results may not apply to patients with mutations in h PMS2 and EpCAM(TACSTD) , as none of our patients had mutations in these genes.
In summary, this is the fi rst study to evaluate Lynch syndrome predictive models in a multi-center and multi-ethnic US referral population. We found that the three models tested, MMRPredict, PREMM(1,2,6), and MMRPro, performed comparably and showed overall improved test characteristics compared with Amsterdam and Bethesda guidelines. Although each model has varying strengths and weaknesses, familiarity with and use of these models can help increase detection of Lynch syndrome and prevent cancer-related morbidity and mortality.
